Docket #0946 Date Filed: 08/20/2026

MCKOOL SMITH, PC
John J. Sparacino (TX Bar No. 18873700)
S. Margie Venus (TX Bar No. 20545900)
600 Travis Street, Suite 7000
Houston, Texas 77002
Telephone: (713) 485-7300
Facsimile: (713) 485-7344
Email: jsparacino@mckoolsmith.com
Email: mvenus@mckoolsmith.com

Travis E. DeArman (TX Bar No. 24074117)
300 Crescent Court, Suite 1200
Dallas, Texas 75201
Telephone: (214) 978-4000
Facsimile: (214) 978-4044
Email: tdearman@mckoolsmith.com

Counsel for Dundon Advisers, LLC, as Liquidating Trustee of the Eiger BioPharmaceuticals Liquidating Trust

PORZIO, BROMBERG & NEWMAN, P.C.
Warren J. Martin Jr. (admitted *pro hac vice*)
Rachel A. Parisi (admitted *pro hac vice*)
5 Sylvan Way
P.O. Box 218
Parsippany, New Jersey 07054
Telephone: (973) 538-4006
Facsimile: (973) 538-5146
Email: WJMartin@pbnlaw.com
Email: RAParisi@pbnlaw.com

IN THE UNITED STATES BANKRUPTCY COURT
FOR THE NORTHERN DISTRICT OF TEXAS
DALLAS DIVISION

In re:	§	**Chapter 11**
	§	
EIGER BIOPHARMACEUTICALS, INC., *et al.*[1]	§	**Case No. 24-80040 (SGJ)**
	§	
Debtors.	§	**(Jointly Administered)**

SECOND NOTICE OF EXPUNGEMENT OF CLAIMS REGISTER

To: ALL PARTIES LISTED ON THE ATTACHED SCHEDULE 1 AND SCHEDULE 2

[1] The Debtors in these chapter 11 cases, together with the last four digits of each Debtor's federal tax identification number, are: Eiger BioPharmaceuticals, Inc. (1591); EBPI Merger Inc. (9986); EB Pharma LLC (8352); Eiger BioPharmaceuticals Europe Limited (N/A); and EigerBio Europe Limited (N/A). The Debtors' service address is 2100 Ross Ave., Dallas, Texas 75201.

24800402608200000000000001

Dundon Advisers, LLC, in its capacity as liquidating trustee (the "Liquidating Trustee") of the liquidating trust established pursuant to the *Order Approving the Debtors' Amended Disclosure Statement and Confirming the Fifth Amended Joint Plan of Liquidation of Eiger Biopharmaceuticals, Inc. and its Debtor Affiliates* [Docket No. 639] (the "Confirmation Order") confirming the *Fifth Amended Joint Plan of Liquidation of Eiger BioPharmaceuticals, Inc. and its Debtor Affiliates Pursuant to Chapter 11 of the Bankruptcy Code* [Docket No. 635-1] (as amended, or supplemented from time to time, the "Plan[2]"), in the above-captioned Chapter 11 bankruptcy proceedings, hereby provides the following:

PLEASE TAKE NOTICE that the Liquidating Trustee previously filed the *Notice of Expungement of Claims from the Claims Register* on November 13, 2024 [Docket No. 741]. The Liquidating Trustee hereby files this *Second Notice of Expungement of Claims from the Claims Register* to provide notice of the additional claims that have been expunged in accordance with the Plan.

PLEASE TAKE FUTHER NOTICE that the Liquidating Trustee has determined that the claims identified on **Schedule 1** attached hereto were filed after the applicable Bar Date of July 22, 2024. Accordingly, the Claims are untimely and are hereby disallowed and expunged from the Claims Register.

PLEASE TAKE FURTHER NOTICE that the Liquidating Trustee has expunged the Claims listed on the attached **Schedule 2** from the Claims Register because the holders of such Claims failed to return a completed IRS Form W-9 (or applicable W-8/W-8BEN-E) within one hundred eighty (180) days of the Liquidating Trustee's request, as required by the Plan. The Plan

[2] Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to them in the Plan.

provides that:

> *[A]ny party entitled to receive any property as an issuance or distribution under the Plan shall, upon request, provide its social security number or employer or taxpayer identification number as assigned by the IRS and deliver to the withholding agent or such other Person designated by the Liquidating Trustee the appropriate IRS Form or other tax forms (including W-9 or W-8BEN-E) or documentation requested by the Liquidating Trustee to reduce or eliminate any required federal, state, or local withholding. If the party fails to comply with such request within one hundred eighty (180) days from the date of the request, the related issuance or distribution shall irrevocably revert to the Liquidating Trustee, and any claim to such distribution shall be deemed discharged and forever barred.*

See Plan, Art. VI. B. The claims on **Schedule 2** are deemed automatically forfeited and expunged from the Claims Register pursuant to the Plan, and the holders of such Claims shall not be entitled to receive any further distributions on account of such Claims under the Plan absent further order of the Bankruptcy Court.

[*Remainder of page intentionally left blank.*]

Dated: August 20, 2026

/s/ S. Margie Venus

MCKOOL SMITH, PC
John J. Sparacino (TX Bar No. 18873700)
S. Margie Venus (TX Bar No. 20545900)
600 Travis Street, Suite 7000
Houston, Texas 77002
Telephone: (713) 485-7300
Facsimile: (713) 485-7344
Email: jsparacino@mckoolsmith.com
Email: mvenus@mckoolsmith.com

Travis E. DeArman (TX Bar No. 24074117)
300 Crescent Court, Suite 1200
Houston, Texas 75201
Telephone: (214) 978-4000
Facsimile: (214) 978-4044
Email: tdearman@mckoolsmith.com

PORZIO, BROMBERG & NEWMAN, P.C.
Warren J. Martin Jr. (admitted *pro hac vice*)
Rachel A. Parisi (admitted *pro hac vice*)
5 Sylvan Way
P.O. Box 218
Parsippany, New Jersey 07054
Telephone: (973) 538-4006
Facsimile: (973) 538-5146
Email: WJMartin@pbnlaw.com
Email: RAParisi@pbnlaw.com

Counsel for the Liquidating Trustee

Schedule 1

SCHEDULE 1

EIGER BIOPHARMACEUTICALS, INC., ET AL. CASE NO. 24-80040
Late Filed Claims

Name	**Date Filed**	**Schedule/Claim Number**	**Asserted Classification**	**Asserted Amount**
Altasciences Company Inc.	1/31/2025	100	General Unsecured Claim	$80,262.00
Dr Tracey L McLaughlin	1/12/2026	101	General Unsecured Claim	$25,779.45

Schedule 2

SCHEDULE 2

EIGER BIOPHARMACEUTICALS, INC., ET AL. CASE NO. 24-80040
Claims Without Required W-9 or Tax Forms

Schedule/Claims No.	**Name**	**Amount Asserted**
3299893	ABC-PLAN, INC.	$1,887.10
21	ADAMAS Consulting LLC	$1,752.65
1	Broadridge Financial Solutions	$21,561.86
24	Donnelley Financial Solutions	$15,270.75
3299814	ELDON CUNNINGHAM MAYER III	$44,000.00
3299824	FEDERAL EXPRESS CORPORATION	$262.04
99	MARKETSPHERE CONSULTING, LLC	$962.50
3299906	NICHE QUALITY	$1,807.05
53	Pharmaceutical Research Associates Inc, affiliate of ICON Clinical Research Limited	$658.79
20	Platform Life Sciences Inc	$67,035.00
3299858	QUENCH USA, INC	$337.16
3299882	REGULATORY PHARMA NET S.R.L.	$498.83
3299780	RHUFELLE NICOLE FEREIRA	$416.00
3299884	ROPES & GRAY LLP	$3,335.00
18	Statistics Collaborative, Inc.	$1,312.50
3299868	TEPPER & EYSTER, PLLC	$162.50
3299864	TRIALOG CLINICAL TRIALS LTD	$1,990.00
3299821	TRINET	$1,479.08